Biomarkers /
G6PD
Overview
G6PD is altered in 1.27% of all cancers with endometrial endometrioid adenocarcinoma, colon adenocarcinoma, high grade ovarian serous adenocarcinoma, low grade ovarian serous adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].
The most common alterations in G6PD are G6PD Mutation (1.19%), G6PD L203M (0.44%), G6PD R454C (0.77%), G6PD V291M (0.77%), and G6PD A335T (0.39%) [3].
Clinical Trials
Significance of G6PD in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.